Project Grant R01AA032025
- Federal Project Grant Summary Louisiana State University received a $1,192,109 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded August 15, 2025, with completion targeted for April 30, 2030. The grant supports mechanistic research on epigenetic regulation of stress-potentiated ethanol drinking, specifically investigating the role of G9A, a histone methyltransferase, in alcohol use disorder (AUD) within the...
- Federal Project Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Louisiana State University Health Sciences Center-Shreveport a Project Grant of $321,929 (awarded May 1, 2026; completion date January 31, 2031) under the Alcohol Research Programs (CFDA 93.273) to conduct fundamental research investigating the neurobiological mechanisms underlying alcohol tolerance development. The research will examine the role of neurogranin (NG) in regulating nitric...
- Federal Grant Award Summary Louisiana State University Health Sciences Center New Orleans received a $1,012,500 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 5, 2025, with completion scheduled for May 31, 2030. The grant funds research investigating the neural mechanisms by which social stress escalates alcohol consumption, with specific focus on kappa opioid receptor (KOR) modulation in...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded The Medical University of South Carolina a Project Grant totaling $459,707 on September 5, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate the neurobiological mechanisms underlying alcohol use disorder (AUD). The award funds a five-year research initiative extending through May 31, 2030, examining how chronic intermittent ethanol exposure alters astrocyte physiology,...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $2.55 million Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 5, 2025, with completion targeted for August 31, 2029. The grant supports research investigating the insula-bed nucleus of the stria terminalis (BNST) neural circuit's role in regulating alcohol use disorder (AUD). The research project focuses on...
- Federal Grant Award Summary Funding Agency: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Federal Grant Program: Alcohol Research Programs (CFDA 93.273) Award Amount: $559,180 Award Date: September 1, 2025 Project Period: September 1, 2025 – June 30, 2030 Awardee: RTI International (Research Triangle Institute), Research Triangle Park, North Carolina RTI International will conduct multi-omic research to identify neurobiological factors underlying alcohol use disorder (AUD) with...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded Boston University Medical Campus a $580,556 project grant under the Alcohol Research Programs (CFDA 93.273) beginning May 1, 2026, with completion targeted for January 31, 2031. This research initiative investigates the role of pituitary adenylate cyclase activating polypeptide (PACAP) in the extended amygdala's regulation of heavy alcohol drinking and associated anxiety-like behaviors. The project...
- Federal Project Grant Award Summary The Medical University of South Carolina received a $151,040 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), effective March 9, 2026, with completion scheduled for November 30, 2027. This award supports fundamental neuroscience research investigating the role of orexinergic neurons in alcohol dependence and excessive ethanol consumption. The research employs advanced...
- Federal Project Grant Award Summary The University of Minnesota received a $157,040 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded on March 9, 2026, with completion scheduled for January 30, 2028. This research project investigates the underlying neural mechanisms driving compulsive alcohol consumption despite negative consequences, a defining feature of alcohol use disorder (AUD). The research delivers...
- Federal Project Grant Award Summary Tulane University received a $219,938 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) effective September 26, 2025, with a completion date of August 31, 2027. The award supports fundamental biomedical research investigating plasma membrane rupture (PMR) in alcohol-associated hepatitis (AH), a severe and potentially life-threatening form of alcohol-associated liver disease...
Louisiana State University Health Sciences Center New Orleans is conducting preclinical research on a nonmuscle myosin II inhibitor (NMIII) as a novel therapeutic intervention for alcohol use disorder (AUD), funded by the National Institute on Alcohol Abuse and Alcoholism under the Alcohol Research Programs (CFDA 93.273). The project, awarded $567,832 on June 1, 2026, with an expected completion date of April 30, 2031, aims to develop and test a first-in-class NMIII compound to reduce alcohol-seeking behavior and drinking in dependent animal models. The research builds on preliminary findings demonstrating that systemic NMIII administration paired with alcohol exposure disrupts the reconsolidation of alcohol-related memories by targeting actin dynamics and structural plasticity in the basolateral amygdala, a key brain region associated with addiction-related learning and relapse behavior. This project advances the fundamental knowledge base for alcohol treatment by exploring a mechanistically novel approach to disrupting the neural substrates that maintain alcohol-related memories and motivational responses to environmental cues. The work supports ongoing medication development efforts, including an investigational new drug (IND) filing planned for the third quarter of the award period, with the ultimate goal of translating preclinical findings into a clinically viable therapeutic option for patients who fail to respond to or comply with current AUD treatments.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $567.8k | 5/27/26 |